Overview

Welcome to Javelin Pharmaceuticals Investor Relations. We are a specialty pharmaceutical company that applies innovative proprietary technologies to develop new drugs and improved formulations of existing drugs that target current unmet and underserved medical need in the pain management market. Our drug candidates address the acute moderate-to-severe pain medication market segment. We are developing differentiated pain control products that provide the flexibility and versatility required to address the limitations of existing prescription pain medications in supervised health care settings. Javelin has three late stage product candidates in development: Dyloject™ (diclofenac sodium, injectable), Rylomine™ (intranasal morphine) and PMI-150 (intranasal ketamine).

Recent Releases

6/10/2008
Javelin Pharmaceuticals Enrolls First Patient in Pivotal Trial for PMI-150

6/5/2008
Javelin Pharmaceuticals' Founder and President Transitions to Executive Director

more »

Events

5/14/2008 8:30 AM ET
First Quarter 2008 Earnings Call

3/17/2008 4:00 PM ET
Cowen & Company's 28th Annual Health Care Conference

more »

CONTACT US   JOIN US   SITE MAP
© 2008 Javelin Pharmaceuticals,Inc. / Intrac,Inc. / IDDS,Inc. All rights reserved. All other trademarks are the properties of their respective owners. Reproduction in whole or in part in any form or medium without express written permission of Javelin Pharmaceuticals,Inc. / Intrac,Inc. /IDDS,Inc. is prohibited.